Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.66 |
| ▸ | NMT2 | O60551 | 5/20 | 0.66 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
| ▸ | CHRND | Q07001 | 6/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.43 |
| ▸ | CHRNG | P07510 | 2/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29300386 | 0.89 | NMT1 (0.62) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL29299860 | 0.85 | NMT1 (0.55) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL27392056 | 0.85 | NMT1 (0.55) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL29300381 | 0.83 | NMT2 (0.54) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL29300401 | 0.80 | LMNA (0.46) | NMT1NMT2 | |
| SCHEMBL29299856 | 0.79 | NMT1 (0.58) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL16328616 | 0.79 | NMT1 (0.51) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL29237467 | 0.79 | CASP2 (0.47) | NMT1NMT2 | |
| SCHEMBL23587547 | 0.78 | NMT1 (0.59) | NMT1NMT2TLR2SIRT6SIRT1 | |
| SCHEMBL24654168 | 0.76 | SIRT6 (0.48) | NMT1NMT2TLR2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226343-A1 | NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF | NPY1R, NPY2R, NPY4R | NMT1 1314/4885NMT2 1308/4885TLR2 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.